Last updated: 11/07/2018 18:49:27
A Randomised, Double-Blind, Double-Dummy, Parallel-Group Comparison of Seretide. Diskus/Accuhaler. 250/50 mg bid with Budesonide 800 mg bid plus Formoterol 12.0 mg bid (both via Breath-Actuated Dry Powder Inhaler) in Adolescent and Adult Moderate-Severe Asthmatics
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Randomised, Double-Blind, Double-Dummy, Parallel-Group Comparison of Seretide. Diskus/Accuhaler. 250/50 mg bid with Budesonide 800 mg bid plus Formoterol 12.0 mg bid (both via Breath-Actuated Dry Powder Inhaler) in Adolescent and Adult Moderate-Severe Asthmatics
Trial description: A Randomised, Double-Blind, Double-Dummy, Parallel-Group Comparison of Seretide. Diskus/Accuhaler. 250/50 mg bid with Budesonide 800 mg bid plus Formoterol 12.0 mg bid (both via Breath-Actuated Dry Powder Inhaler) in Adolescent and Adult Moderate-Severe Asthmatics
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Letter to Editor: Ringdal N and Whitehead P. Respir Med 2003; 97:447-448.
Ringdal N, Chuchalin A, Chovan L, Tudoric N, Maggi E and Whitehead PJ on behalf of the EDICT investigators. Evaluation of Different Inhaled Combination Therapies (EDICT): a randomised, double-blind comparison of Seretide™ (50/250 ?g bd Diskus™) versus formoterol (12 ?g bd) and budesonide (800 ?g bd) given concurrently (both via Turbuhaler™) in patients with moderate-to-severe asthma. Respir Med 2002; 96: 851-861.
Medical condition
Asthma
Product
fluticasone propionate/salmeterol
Collaborators
Not applicable
Study date(s)
May 1998 to June 1999
Type
Not applicable
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1999-08-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website